As expected, the results confirmed that simultaneous blockade of VEGF-B and IL-17A could ameliorate renal dysfunction by decreasing renal lipid accumulation and inflammatory response, they also alleviated the renal fibrosis in vivo. Here, VEGFB is linked to renal fibrosis.